Valuation Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 224.87 USD | +3.06% |
|
+3.00% | +11.73% |
| 03:23pm | Charles River Laboratories International, Inc. Enters Manufacturing Collaboration with Gazi University | CI |
| 02:24pm | Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday | MT |
Company Valuation: Charles River Laboratories International, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 12,295 | 18,771 | 10,941 | 12,249 | 9,520 | 10,738 | 10,738 | - |
| Change | - | 52.67% | -41.71% | 11.95% | -22.28% | 12.8% | 0% | - |
| Enterprise Value (EV) 1 | 14,046 | 21,196 | 13,418 | 14,619 | 11,565 | 12,670 | 12,279 | 11,824 |
| Change | - | 50.9% | -36.69% | 8.95% | -20.89% | 9.55% | -3.09% | -3.71% |
| P/E ratio | 34.3x | 48.9x | 22.7x | 25.9x | 931x | 52x | 30.1x | 23.7x |
| PBR | 5.82x | 7.38x | 3.68x | 3.41x | 2.75x | 3.05x | 2.77x | 2.49x |
| PEG | - | 8.8x | 0.9x | -9.44x | -9.5x | 0x | 0.4x | 0.9x |
| Capitalization / Revenue | 4.2x | 5.3x | 2.75x | 2.97x | 2.35x | 2.68x | 2.64x | 2.53x |
| EV / Revenue | 4.8x | 5.99x | 3.37x | 3.54x | 2.86x | 3.16x | 3.01x | 2.78x |
| EV / EBITDA | 20x | 24.1x | 13.5x | 14.4x | 11.6x | 13.1x | 12.4x | 11.3x |
| EV / EBIT | 24x | 28.6x | 16.1x | 17.4x | 14.3x | 16x | 15x | 13.5x |
| EV / FCF | 37x | 39.8x | 45.5x | 40x | 23.1x | 26.7x | 24.4x | 20.1x |
| FCF Yield | 2.71% | 2.51% | 2.2% | 2.5% | 4.34% | 3.74% | 4.11% | 4.97% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.2 | 7.6 | 9.48 | 9.22 | 0.2 | 4.193 | 7.245 | 9.219 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2,924 | 3,540 | 3,976 | 4,129 | 4,050 | 4,006 | 4,074 | 4,250 |
| EBITDA 1 | 701.3 | 879.5 | 990.9 | 1,013 | 996.1 | 966.2 | 988.7 | 1,047 |
| EBIT 1 | 585 | 742.1 | 834 | 838.8 | 805.9 | 793.9 | 817.4 | 876.1 |
| Net income 1 | 364.3 | 391 | 486.2 | 474.6 | 10.3 | 215 | 380.9 | 440.4 |
| Net Debt 1 | 1,751 | 2,425 | 2,477 | 2,370 | 2,046 | 1,932 | 1,541 | 1,086 |
| Reference price 2 | 247.17 | 371.96 | 215.04 | 238.78 | 186.16 | 218.19 | 218.19 | 218.19 |
| Nbr of stocks (in thousands) | 49,743 | 50,464 | 50,879 | 51,297 | 51,136 | 49,215 | 49,215 | - |
| Announcement Date | 17/02/21 | 16/02/22 | 22/02/23 | 14/02/24 | 19/02/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 52.03x | 3.16x | 13.11x | -.--% | 10.74B | |
| 37.79x | 5.5x | 18.4x | 0.9% | 48.34B | |
| 32.91x | 3.28x | 14.06x | -.--% | 39.8B | |
| 102.27x | 6.54x | 65.78x | -.--% | 36.99B | |
| 54.65x | 11.21x | 31.16x | 0.35% | 30.67B | |
| -20.8x | 6035.16x | -19.72x | -.--% | 22.47B | |
| 40.7x | 6.6x | 29.98x | -.--% | 16.97B | |
| Average | 42.79x | 867.35x | 21.83x | 0.18% | 29.43B | |
| Weighted average by Cap. | 45.53x | 663.78x | 24.49x | 0.26% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- CRL Stock
- Valuation Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition